Third, CTNNB1 mutations have also been identified in a subset of clinical HCC specimens, suggesting that there may be clinical cases in which the therapeutic efficacy of INTS6-saRNA is uncertain [42]. This evidence concerns the gene INTS6 and hepatocellular carcinoma.